Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 06, 2019 08:00 ET | Source: Savara Inc.

Savara Provides Update on IMPALA and AVAIL Pivotal Clinical Studies

AUSTIN, Texas, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on its two pivotal Phase 3 clinical studies, IMPALA and AVAIL. ...
December 19, 2018 08:00 ET | Source: Savara Inc.

Savara Announces Interim Results for OPTIMA Clinical Study of Molgradex for the Treatment of NTM

AUSTIN, Texas, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced interim results from OPTIMA, a Phase 2a clinical study evaluating its...
November 16, 2018 08:00 ET | Source: Savara Inc.

Savara to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27th

AUSTIN, Texas, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, announced today that Rob Neville, Savara’s Chief Executive Officer, will participate in a...
November 07, 2018 16:02 ET | Source: Savara Inc.

Savara Reports Third Quarter 2018 Financial Results and Provides Business Update

Completed Enrollment in Two Clinical Studies of Molgradex: IMPALA, a Pivotal Phase 3 Study and OPTIMA, a Phase 2a StudyIMPALA Top Line Results Expected Q2 2019OPTIMA Interim Results Expected Q4 2018 ...
October 31, 2018 08:00 ET | Source: Savara Inc.

Savara Completes Enrollment in Molgradex OPTIMA Clinical Study for the Treatment of NTM

Interim Results Expected in Q4 2018 AUSTIN, Texas, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced completion of the target enrollment...
August 09, 2018 16:03 ET | Source: Savara Inc.

Savara Reports Second Quarter 2018 Financial Results and Provides Positive Business Update

Molgradex Phase 3 IMPALA study enrollment on track for completion in Q3 2018AeroVanc Phase 3 AVAIL study enrollment on track for completion in Q1 2019Molgradex Phase 2a OPTIMA study enrollment on...